Business
PDS Biotechnology partners with NCI
PDS Biotechnology partners with NCI.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 5158O NetScientific PLC 09 February 2016 \n\n \nNetScientific plc\nPDS Biotechnology partners with National Cancer Institute in Phase II clinical trials for novel cancer immunotherapies\nLondon, UK - 9 February 2016 - NetScientific plc (\"NetScientific\" or the \"Group\", AIM: NSCI), the transatlantic biomedical and healthcare technology group, is pleased to note that one of its portfolio companies, PDS Biotechnology, has signed a Cooperative Research and Development Agreement with the National Cancer Institute, a division of the US National Institutes of Health. The goal is to co-develop novel cancer immunotherapies through Phase II clinical trials that will start in 2016 and 2017.\nCommenting on the news, NetScientific's Chief Executive Officer, Francois R. Martelet said: \"Securing a cooperative research and development agreement with the leading cancer research institute in the US is a landmark moment for PDS Biotechnology and a huge endorsement of its technology. Versamune® has been shown to be applicable to potentially a wide range of cancers and this deal will be key to further advancing immunotherapy clinical research.\"\nThe full text of the announcement from PDS Biotechnology can be found below.\nContact Details\n\n\n\n\nNetScientific\nFrançois R. Martelet, M.D., CEO\nMark Nanovich, Interim CFO\n\n\nTel: +44 (0)20 3514 1800\n\n\n\n\n \nInvestec (NOMAD and broker)\nGary Clarence / Daniel Adams\n\n\nTel: +44 (0)20 7597 4000\n\n\n\n\n \nInstinctif Partners\nMelanie Toyne-Sewell / Jayne Crook / Rosanna Forrest\n\n\nTel: +44 (0)20 7457 2020 Email: [email protected]\n\n\n\n\n \n \nPDS Biotechnology Signs Agreement with National Cancer Institute to form Phase II clinical collaboration for novel cancer immunotherapies based on PDS' Versamune® platform technology\n \n \n-Clinical Co-Development of Immunotherapies to treat Prostate, Breast, and HPV-related Cancers-\n \nNorth Brunswick, New Jersey February 9, 2016 (PR NEWSWIRE) - PDS Biotechnology (PDS), a clinical-stage biopharmaceutical company focused on developing a pipeline of simpler, safer and more effective cancer immunotherapies based on its novel Versamune® platform, today announced that the Company has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer ...